In this project, we propose to develop and evaluate a novel VCN-based positron emission tomography (PET) imaging agent with the hypothesis that VCN will provide a unique objective noninvasive method to evaluate treatment response. At the completion of this preclinical project, we will be immediately ready to commence a clinical trial in men with metastatic prostate cancer that will have a high impact on patient care by providing new objective imaging-based means for deciphering the effectiveness of various treatments in a personalized patient-specific manner.

NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.